CoChat

Three European Retrospective Real-World Chart Review Studies to Determine the Effectiveness of Flash Glucose Monitoring on HbA1c in Adults with Type 2 Diabetes

Open access
Kröger, Jens, Fasching, Peter, Hanaire, Hélène · 2020 · Diabetes Therapy

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: The impact of flash glucose monitoring technology on HbA1c in type 2 diabetes managed by basal bolus insulin is uncertain. Three parallel European retrospective non-interventional chart review studies collected data reported in medical records. Each country's study aim was to determine the effectiveness of the device on HbA1c when used by their population for 3-6 months as their standard of care for management of glycaemia in a real-world setting. METHODS: Medical records were eligible for adult patients with type 2 diabetes, on a basal bolus insulin regimen for 1 year or more, device use for 3 months or more before the start of the study, an HbA1c concentration up to 3 months prior to starting device use (patients were using blood glucose monitoring for self-management) between 64 and 108 mmol/mol (8.0-12.0%) plus an HbA1c determination 3-6 months after commencing flash glucose monitoring use. RESULTS: Records were analysed from 18 medical centres in Austria (n = 92), France (n = 88) and Germany (n = 183). Baseline HbA1c results, recorded up to 90 days before the start of device use, were comparable across the three countries and were reduced significantly by 9.6 ± 8.8 mmol/mol mean ± SD (Austria [0.9 ± 0.8%], p < 0.0001), 8.9 ± 12.5 mmol/mol (France [0.8% ± 1.1], p < 0.0001) and 10.1 ± 12.2 mmol/mol (Germany [0.9% ± 1.1], p < 0.0001). No significant differences were detected between age group, sex, BMI or duration of insulin use. CONCLUSIONS: Three European real-world, chart review studies in people with type 2 diabetes managed using basal bolus insulin therapy each concluded that HbA1c was significantly reduced after changing to use of flash glucose monitoring for 3-6 months in a real-world setting.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s13300-019-00741-9

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Mean and 95% confidence interval for change in HbA1c between baseline and final for Austria, France, Germany and overall. Overall effect size − 9.7 mmol/mol (95% Confidence Interval − 10.9 to − 8.5)I2 = 0 (Cochran’s Q = 0.7, p = 0.7113)
Fig. 1 Mean and 95% confidence interval for change in HbA1c between baseline and final for Austria, France, Germany and overall. Overall effect size − 9.7 mmol/mol (95% Confidence Interval − 10.9 to − 8.5)I2 = 0 (Cochran’s Q = 0.7, p = 0.7113)CC BY-NC · PubMed Central
Fig. 2 Change in HbA1c sensitivity analysis for narrower time intervals of final HbA1c (mean and 95% confidence interval)
Fig. 2 Change in HbA1c sensitivity analysis for narrower time intervals of final HbA1c (mean and 95% confidence interval)CC BY-NC · PubMed Central
Fig. 3 Change in HbA1c for each month of the 3–6 months after start of device use (mean and 95% confidence interval)
Fig. 3 Change in HbA1c for each month of the 3–6 months after start of device use (mean and 95% confidence interval)CC BY-NC · PubMed Central
Fig. 4 Change in HbA1c by baseline HbA1c, age group, sex, duration of insulin therapy and BMI (mean and 95% confidence interval). HbA1c < 75 and ≥ 75 mmol/mol, BMI < 30 and ≥ 30 kg/m2
Fig. 4 Change in HbA1c by baseline HbA1c, age group, sex, duration of insulin therapy and BMI (mean and 95% confidence interval). HbA1c < 75 and ≥ 75 mmol/mol, BMI < 30 and ≥ 30 kg/m2CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Cited by

See all 97

Metadata

Authors
Kröger, J., Fasching, P., & Hanaire, H.
Affiliations
  • Wilhelminen Hospital (AT)
  • Centre Hospitalier Universitaire de Toulouse (FR)
Corresponding author
Kröger, Jens
Venue
Diabetes Therapy
Published
2019-12-12
Volume
11
Issue
1
Pages
279-291
ISSN
  • 1869-6953 (ISSN-L)
  • 1869-6961
OpenAlex
W2995322095
Cited by
90
References
23
Citations by year
2026: 5 · 2025: 8 · 2024: 13 · 2023: 12 · 2022: 19 · 2021: 26 · 2020: 6 · 2019: 1
FWCI
10.55
Type
journal article
Language
en
Open access
Licence
Locations
  • Diabetes Therapy (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
Abbott Diabetes Care
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
Keywords
flash glucose monitoring, type 2 diabetes, HbA1c, multiple daily insulin injections, glycemic control, real-world effectiveness, continuous glucose monitoring, self-monitoring of blood glucose

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Three European Retrospective Real-World Chart Review Studies to Determine the Effectiveness of Flash Glucose Monitoring on HbA1c in Adults with Type 2 Diabetes. https://app.cochat.ai/papers/10.1007/s13300-019-00741-9
The paper
Kröger, J., Fasching, P., & Hanaire, H. (2020). Three European Retrospective Real-World Chart Review Studies to Determine the Effectiveness of Flash Glucose Monitoring on HbA1c in Adults with Type 2 Diabetes. Diabetes Therapy. https://doi.org/10.1007/s13300-019-00741-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.